Advertising

AbbVie Inc.

ABBV-N

NYSE:ABBV

115.08
1.17 (1.01%)
AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories.
More at Wikipedia

Analysis and Opinions about ABBV-N

Signal
Opinion
Expert
Chart
COMMENT
COMMENT
June 28, 2021
https://finance.yahoo.com/news/abbvies-abbv-rinvoq-snda-decision-114811600.html AbbVie announced that the FDA won't grant a decision on the application of AbbVie's arthritis drug, Rinvoq (though it has been approved in Europe). He's very disappointment that AbbVie has not gotten the FDA vote through. If Runvoq does not pass, it could be very bad for Abbvie. He is very concerned.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
June 28, 2021
https://finance.yahoo.com/news/abbvies-abbv-rinvoq-snda-decision-114811600.html AbbVie announced that the FDA won't grant a decision on the application of AbbVie's arthritis drug, Rinvoq (though it has been approved in Europe). He's very disappointment that AbbVie has not gotten the FDA vote through. If Runvoq does not pass, it could be very bad for Abbvie. He is very concerned.
BUY
BUY
June 15, 2021

Trades at 10x earnings. Fine fundamentals. Owns Humera, a hugely profitable drug. ABBV bought Allergan to dilute the dependence on Humera revenues. That's when he bought ABBV, because the company became less risky. A fine 4.5% dividend. Caveat: in 2023, Humera goes off-patent, so ABBV has been busy replacing these future lost revenues (so they bought Allergan). They also have been developing and acquiring new drugs. Worries of going off-patent are already built in share prices, so the worry is in the past.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
June 15, 2021

Trades at 10x earnings. Fine fundamentals. Owns Humera, a hugely profitable drug. ABBV bought Allergan to dilute the dependence on Humera revenues. That's when he bought ABBV, because the company became less risky. A fine 4.5% dividend. Caveat: in 2023, Humera goes off-patent, so ABBV has been busy replacing these future lost revenues (so they bought Allergan). They also have been developing and acquiring new drugs. Worries of going off-patent are already built in share prices, so the worry is in the past.

Gordon Reid
Price
$115.745
Owned
Yes
BUY
BUY
May 25, 2021

A great holding. Pays nearly a 5% dividend yield. They bought Allergan some years ago. Humera used to be a big chunk of company revenues, but is now lower and more comfortable. Cash flow is strong. Earnings valuation is attraction. Caveat: humera goes off patent in 2023, so this will impact Abbvie's revenue stream. However, ABBV is smart by lowering the impact of humera by developing other drugs that bring in $1 billion revenues. The humera factor is fully discounted in the current Abbvie price. So, he would absolutely buy ABBV. You're now buying it at a 20% discount if ABBV didn't have that patent-expiration overhang.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
May 25, 2021

A great holding. Pays nearly a 5% dividend yield. They bought Allergan some years ago. Humera used to be a big chunk of company revenues, but is now lower and more comfortable. Cash flow is strong. Earnings valuation is attraction. Caveat: humera goes off patent in 2023, so this will impact Abbvie's revenue stream. However, ABBV is smart by lowering the impact of humera by developing other drugs that bring in $1 billion revenues. The humera factor is fully discounted in the current Abbvie price. So, he would absolutely buy ABBV. You're now buying it at a 20% discount if ABBV didn't have that patent-expiration overhang.

Gordon Reid
Price
$114.530
Owned
Yes
BUY
BUY
May 14, 2021

There are some fears of loosing patent protection with Humera, but patients seem to be want to stick with the brand name. When they acquired Allergan, they got the botox franchise, which is a reopening play. 4.5% yield. A good long term play. They have a good pipeline as well.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
May 14, 2021

There are some fears of loosing patent protection with Humera, but patients seem to be want to stick with the brand name. When they acquired Allergan, they got the botox franchise, which is a reopening play. 4.5% yield. A good long term play. They have a good pipeline as well.

JoAnne Feeney
Price
$116.910
Owned
Yes
TOP PICK
TOP PICK
April 27, 2021
Stockchase Research Editor: Michael O'Reilly ABBV is one of the highest quality pharma stocks you can own with a $194 billion market cap and is a good defensive holding paying an excellent dividend (backed by a payout ratio of 50% of cash flow). Best known for its Crohn's disease treatment Humira, which provided over $19 billion in revenue last year. We would buy this with a stop loss at $90, looking to achieve $125 -- upside potential over 11%. Not a growth stock, but a good dividend payer. Yield 4.45% (Analysts’ price target is $122.17)
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 27, 2021
Stockchase Research Editor: Michael O'Reilly ABBV is one of the highest quality pharma stocks you can own with a $194 billion market cap and is a good defensive holding paying an excellent dividend (backed by a payout ratio of 50% of cash flow). Best known for its Crohn's disease treatment Humira, which provided over $19 billion in revenue last year. We would buy this with a stop loss at $90, looking to achieve $125 -- upside potential over 11%. Not a growth stock, but a good dividend payer. Yield 4.45% (Analysts’ price target is $122.17)
PAST TOP PICK
PAST TOP PICK
April 13, 2021

(A Top Pick May 12/20, Up 24%) He's sticking with it. There's more upside to come. Their biggest product was Humera, a massive drug. A few years ago, they bought Allergan and their Botox drug, which reduced company dependence on Humera for company revenues. ABBV has some new drugs in the pipeline that are reaching $1 billion in sales, so this further spreads the risk away from Humera. It trades at a cheap 9x PE and pays a 5% dividend. Warning: in 2023, Humera goes off patent and that will mean a challenge for ABBV to replace that revenue stream (Humera makes up 32% of all revenues, though it used to be 65% before Botox).

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 13, 2021

(A Top Pick May 12/20, Up 24%) He's sticking with it. There's more upside to come. Their biggest product was Humera, a massive drug. A few years ago, they bought Allergan and their Botox drug, which reduced company dependence on Humera for company revenues. ABBV has some new drugs in the pipeline that are reaching $1 billion in sales, so this further spreads the risk away from Humera. It trades at a cheap 9x PE and pays a 5% dividend. Warning: in 2023, Humera goes off patent and that will mean a challenge for ABBV to replace that revenue stream (Humera makes up 32% of all revenues, though it used to be 65% before Botox).

Gordon Reid
Price
$107.970
Owned
Yes
BUY WEAKNESS
BUY WEAKNESS
March 17, 2021
There was an issue with a key drug of theirs today (the FDA delayed reviewing it for 3 months). He suspects this is just a speed bump, expects a downgrade or two tomorrow, but this is a buying opportunity.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
March 17, 2021
There was an issue with a key drug of theirs today (the FDA delayed reviewing it for 3 months). He suspects this is just a speed bump, expects a downgrade or two tomorrow, but this is a buying opportunity.
Jim Cramer - Mad Money
Price
$105.040
Owned
Unknown
BUY
BUY
February 12, 2021
It beat earnings, but has struggled the past week. It stalled because people can't get their Botox (a big part of their business) during the lockdown, but ABBV's migraine franchise is fine and the drugs replacing Humera, their big product, are working. Also, this is cheap at 8x earnings and it pays a 5% yield. A bargain now.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 12, 2021
It beat earnings, but has struggled the past week. It stalled because people can't get their Botox (a big part of their business) during the lockdown, but ABBV's migraine franchise is fine and the drugs replacing Humera, their big product, are working. Also, this is cheap at 8x earnings and it pays a 5% yield. A bargain now.
Jim Cramer - Mad Money
Price
$104.440
Owned
Unknown
TOP PICK
TOP PICK
February 11, 2021

Large cap biotech. Humera generates $20B a year in revenue. Exceptional job at using that cashflow to diversify, as in buying Allergan. 15% EPS, clean balance sheet. Its value will eventually be realized. Yield is 5%. (Analysts’ price target is $121.05)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 11, 2021

Large cap biotech. Humera generates $20B a year in revenue. Exceptional job at using that cashflow to diversify, as in buying Allergan. 15% EPS, clean balance sheet. Its value will eventually be realized. Yield is 5%. (Analysts’ price target is $121.05)

Paul MacDonald
Price
$103.650
Owned
Yes
BUY
BUY
December 16, 2020

All big pharmas have been treading water. Patent legislation left them with a leaky boat. He's gravitated toward the bio-pharmas. His favourite in that space is AbbVie, as it's good on fundamentals and financials, inexpensive, very fine dividend, great cashflow generator.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
December 16, 2020

All big pharmas have been treading water. Patent legislation left them with a leaky boat. He's gravitated toward the bio-pharmas. His favourite in that space is AbbVie, as it's good on fundamentals and financials, inexpensive, very fine dividend, great cashflow generator.

Gordon Reid
Price
$104.280
Owned
Yes
COMMENT
COMMENT
December 11, 2020
This discuss their immunology franchise on Monday. If they can present good numbers on new drugs to replace Humera--their biggest-selling drug, but is losing patent protection soon--this will take pressure off this drug and this stock will climb futher. ABBV has a lot of growth and pays a good yield.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
December 11, 2020
This discuss their immunology franchise on Monday. If they can present good numbers on new drugs to replace Humera--their biggest-selling drug, but is losing patent protection soon--this will take pressure off this drug and this stock will climb futher. ABBV has a lot of growth and pays a good yield.
Jim Cramer - Mad Money
Price
$106.340
Owned
Unknown
BUY
BUY
November 19, 2020
You would own it for the strong yield at 5.25%. Valuation is quite cheap relative to peers. Good earnings growth and dividend growth. They raised their guidance which is positive. The split congress helps this name since pushing drug prices down will be harder.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 19, 2020
You would own it for the strong yield at 5.25%. Valuation is quite cheap relative to peers. Good earnings growth and dividend growth. They raised their guidance which is positive. The split congress helps this name since pushing drug prices down will be harder.
Stan Wong
Price
$99.450
Owned
Yes
BUY
BUY
October 23, 2020

Likes it. A spin-off of Abbott Labs. They have made a purchase of Allergan that diluted the concentration of Humira. The company will get its legs so buy it and be patient.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
October 23, 2020

Likes it. A spin-off of Abbott Labs. They have made a purchase of Allergan that diluted the concentration of Humira. The company will get its legs so buy it and be patient.

Gordon Reid
Price
$84.340
Owned
Yes
TOP PICK
TOP PICK
October 20, 2020

A sort of contrarian call. Humera is their primary drug (US$19.5 billion annually) used for various immunology disorders. Competitors will nip at their heels here, of course, given that success. They have this drug through 2023. As importantly, they bought Allergan, makers of botox, which is executing. Pays a .5.5% dividend and trades at 7x earnings. There's a disconnect between company value/performance and market perception. A great balance sheet to support the dividend. (Analysts’ price target is $110.26)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
October 20, 2020

A sort of contrarian call. Humera is their primary drug (US$19.5 billion annually) used for various immunology disorders. Competitors will nip at their heels here, of course, given that success. They have this drug through 2023. As importantly, they bought Allergan, makers of botox, which is executing. Pays a .5.5% dividend and trades at 7x earnings. There's a disconnect between company value/performance and market perception. A great balance sheet to support the dividend. (Analysts’ price target is $110.26)

Paul MacDonald
Price
$84.760
Owned
Yes
DON'T BUY
DON'T BUY
October 14, 2020

Owns Abbott Labs instead, as it's more diversified. ABBV is pure pharma. They need to broaden reliance on a few key drugs.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
October 14, 2020

Owns Abbott Labs instead, as it's more diversified. ABBV is pure pharma. They need to broaden reliance on a few key drugs.

TOP PICK
TOP PICK
October 5, 2020
An interesting thing happened during the first U.S. presidential mudslinging, I mean, debate earlier this week: neither side bashed pharma. High drug prices for Americans (who lack universal healthcare) weren't mentioned. As a rule, they are during campaigns, and as an outcome, drug stocks take a hit. It's different in 2020 when the world is waiting for big health companies to solve Covid. AbbVie is part of this army, though it isn't leading the charge like AstraZeneca or Becton Dickinson. Rather, AbbVie is a buy after the company bought Allergan and its slate of drugs. This purchase took the burden off Humira, a hugely popular anti-arthritis drug which made up 63% of company revenues. The problem is the patents for Humira expire around the world by 2023. The Humira deal, which closed last May, fills this void by offering new, key drugs, namely Botox.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
October 5, 2020
An interesting thing happened during the first U.S. presidential mudslinging, I mean, debate earlier this week: neither side bashed pharma. High drug prices for Americans (who lack universal healthcare) weren't mentioned. As a rule, they are during campaigns, and as an outcome, drug stocks take a hit. It's different in 2020 when the world is waiting for big health companies to solve Covid. AbbVie is part of this army, though it isn't leading the charge like AstraZeneca or Becton Dickinson. Rather, AbbVie is a buy after the company bought Allergan and its slate of drugs. This purchase took the burden off Humira, a hugely popular anti-arthritis drug which made up 63% of company revenues. The problem is the patents for Humira expire around the world by 2023. The Humira deal, which closed last May, fills this void by offering new, key drugs, namely Botox.
TOP PICK
TOP PICK
September 30, 2020

Dominance of Humira on revenues had given them pause. Since then, it acquired Allergan, which diluted the concentration of Humera. Metrics are wonderful. 12% free cash flow yield. Trades at less than 10x earnings. Great dividend. Lots of runway ahead. Elective surgeries will come back. Anticipate $12.50 EPS this year, and more next. Yield is 5.42%. (Analysts’ price target is $109.35)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
September 30, 2020

Dominance of Humira on revenues had given them pause. Since then, it acquired Allergan, which diluted the concentration of Humera. Metrics are wonderful. 12% free cash flow yield. Trades at less than 10x earnings. Great dividend. Lots of runway ahead. Elective surgeries will come back. Anticipate $12.50 EPS this year, and more next. Yield is 5.42%. (Analysts’ price target is $109.35)

Gordon Reid
Price
$87.820
Owned
Yes
BUY
BUY
September 30, 2020
It hasn't been doing well, because it has an expiration of 2020 for one its key drugs, Humira, and the pandemic has limited elective surgery Botox, which AbbVie owns. These issues will get resolved and the stock will go to $100.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
September 30, 2020
It hasn't been doing well, because it has an expiration of 2020 for one its key drugs, Humira, and the pandemic has limited elective surgery Botox, which AbbVie owns. These issues will get resolved and the stock will go to $100.
Jim Cramer - Mad Money
Price
$87.590
Owned
Unknown
BUY
BUY
August 27, 2020

ABBV vs. PFE Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 27, 2020

ABBV vs. PFE Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.

Gordon Reid
Price
$94.775
Owned
Unknown
BUY
BUY
August 26, 2020

Likes the sector. Also owns Merck, Regeneron, and LZAGY. ABBV is in immunology and oncology. 8x forward earnings, 8% growth rate, pretty fair valuation. Also involved in Covid antibodies. Likes the combination of decent growth and nice dividend of about 5%.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 26, 2020

Likes the sector. Also owns Merck, Regeneron, and LZAGY. ABBV is in immunology and oncology. 8x forward earnings, 8% growth rate, pretty fair valuation. Also involved in Covid antibodies. Likes the combination of decent growth and nice dividend of about 5%.

Stan Wong
Price
$93.545
Owned
Yes
BUY
BUY
July 28, 2020

Allan Tong’s Discover Picks The good thing about this drugmaker is that its arthritis drug, Humira, has been a runaway success, making up 63% of company revenues. The problem with AbbVie is also Humira–it loses patent protection in American in 2023. Read Top 4 BNN Stock Picks to Buy this Summer for our full analysis.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 28, 2020

Allan Tong’s Discover Picks The good thing about this drugmaker is that its arthritis drug, Humira, has been a runaway success, making up 63% of company revenues. The problem with AbbVie is also Humira–it loses patent protection in American in 2023. Read Top 4 BNN Stock Picks to Buy this Summer for our full analysis.

BUY
BUY
July 9, 2020

Healthcare is one of his favourite sectors. 10% growth rate. Value is there. Beta is below S&P. Dividend of 4.7% or so. Good drug pipeline. Covid R&D is pushing the stock up. Allergan acquisition will give EPS a boost.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 9, 2020

Healthcare is one of his favourite sectors. 10% growth rate. Value is there. Beta is below S&P. Dividend of 4.7% or so. Good drug pipeline. Covid R&D is pushing the stock up. Allergan acquisition will give EPS a boost.

Stan Wong
Price
$97.540
Owned
Yes
BUY
BUY
June 17, 2020
It pays a nice dividend and the company is committed to it. The company is hitting its stride. It made a big acquisition that introduced a new business enterprise, focusing on botox. They have the most successful drug in America -- Humara. This is helping to reduce their dependency on revenue from Humara. He recommends it here. Yield 5%
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
June 17, 2020
It pays a nice dividend and the company is committed to it. The company is hitting its stride. It made a big acquisition that introduced a new business enterprise, focusing on botox. They have the most successful drug in America -- Humara. This is helping to reduce their dependency on revenue from Humara. He recommends it here. Yield 5%
Gordon Reid
Price
$96.760
Owned
Yes
COMMENT
COMMENT
June 12, 2020

JNJ vs ABBV? He likes JNJ as a long term winner. It may be too expensive. ABBV was a risky company until they purchased Allergan and diversified their business more. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. They are still tethered to Humara, which has a lot of generics being developed. He would favor ABBV, although it is a little riskier than JNJ.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
June 12, 2020

JNJ vs ABBV? He likes JNJ as a long term winner. It may be too expensive. ABBV was a risky company until they purchased Allergan and diversified their business more. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. They are still tethered to Humara, which has a lot of generics being developed. He would favor ABBV, although it is a little riskier than JNJ.

Greg Newman
Price
$91.765
Owned
_N/A
TOP PICK
TOP PICK
May 12, 2020

Loves it. He shied away from it in the past because its product offering was concentrated. When they were spun-off from Abbot Labs, it was spun-off with the successful rheumetory arthritis drug, Humira, but the drug made up 63% of company revenues, so the risk was high. In the last year, ABBV bought Allergan which should close this quarter after European and US approvals. Allergan is known for Botox. Together, this will be a great company. It trades at less than 9x PE. Pays a fine 5.5% dividend. The merger is accretive immediately. Great freee cash flow. However, they paid $60 billion for Allergan, but they have the cash flow to pay down that debt at very low interest rates. (Analysts’ price target is $96.33)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
May 12, 2020

Loves it. He shied away from it in the past because its product offering was concentrated. When they were spun-off from Abbot Labs, it was spun-off with the successful rheumetory arthritis drug, Humira, but the drug made up 63% of company revenues, so the risk was high. In the last year, ABBV bought Allergan which should close this quarter after European and US approvals. Allergan is known for Botox. Together, this will be a great company. It trades at less than 9x PE. Pays a fine 5.5% dividend. The merger is accretive immediately. Great freee cash flow. However, they paid $60 billion for Allergan, but they have the cash flow to pay down that debt at very low interest rates. (Analysts’ price target is $96.33)

Gordon Reid
Price
$91.760
Owned
Yes
WAIT
WAIT
February 6, 2020
Trades at 38x earnings. Great dividend yield. Prefers something like JNJ, as it has 3 divisions. With pharma, you need these blockbuster drugs. If the pipeline is weak, the stock falls. Much more difficult to own in an election year, as they're the easiest scapegoat. Pharma usually pops up after an election.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 6, 2020
Trades at 38x earnings. Great dividend yield. Prefers something like JNJ, as it has 3 divisions. With pharma, you need these blockbuster drugs. If the pipeline is weak, the stock falls. Much more difficult to own in an election year, as they're the easiest scapegoat. Pharma usually pops up after an election.
Paul Harris, CFA
Price
$87.180
Owned
Unknown
BUY
BUY
February 3, 2020
He likes it. There's a new uptrend after a long downtrend since early 2018. He's like to see strong volumes and support at $80. If so, it could touch $90.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 3, 2020
He likes it. There's a new uptrend after a long downtrend since early 2018. He's like to see strong volumes and support at $80. If so, it could touch $90.
Javed Mirza
Price
$82.300
Owned
Unknown
BUY
BUY
January 17, 2020
On international drug pricing, it is one of the proposals from Trump. The reason why it's coming to the forefront is because they haven't been able to accomplish anything. The proposal is to initiate a pilot project. Their highest selling drug, Humira, has concerns of patent dispute. He saw the Allergen acquisition as a positive for diversifying the risk from the potential dispute.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
January 17, 2020
On international drug pricing, it is one of the proposals from Trump. The reason why it's coming to the forefront is because they haven't been able to accomplish anything. The proposal is to initiate a pilot project. Their highest selling drug, Humira, has concerns of patent dispute. He saw the Allergen acquisition as a positive for diversifying the risk from the potential dispute.
Paul MacDonald
Price
$88.000
Owned
Yes
COMMENT
COMMENT
November 28, 2019
BMY vs ABBV? Doesn't own either one of them at the moment. Both stocks will probably do just fine over the next couple of years. Bristol Myers acquisition of Celgene will give them new drug applications. Be cautious on the Canadian tax implication in this acquisition. AbbVie on the other end is struggling with drugs that have been in the pipeline for a number of years and will start to face generic competition. Well managed companies. More comfortable with Bristol Myers.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 28, 2019
BMY vs ABBV? Doesn't own either one of them at the moment. Both stocks will probably do just fine over the next couple of years. Bristol Myers acquisition of Celgene will give them new drug applications. Be cautious on the Canadian tax implication in this acquisition. AbbVie on the other end is struggling with drugs that have been in the pipeline for a number of years and will start to face generic competition. Well managed companies. More comfortable with Bristol Myers.
Bruce Murray
Price
$88.330
Owned
No
TOP PICK
TOP PICK
November 27, 2019
Acquiring Allergan. Knock on it was that Humera made up 60% of revenues. Purchase of Allergan dilutes that concentration, and will be 10% accretive in Year 1. Expected revenue growth of 10%, whereas peer group is 3.1%. Trading at less than 10x. Free cashflow, after the dividend, of over 5%. Compelling opportunity. Yield is 5.34%. (Analysts’ price target is $95.45)
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 27, 2019
Acquiring Allergan. Knock on it was that Humera made up 60% of revenues. Purchase of Allergan dilutes that concentration, and will be 10% accretive in Year 1. Expected revenue growth of 10%, whereas peer group is 3.1%. Trading at less than 10x. Free cashflow, after the dividend, of over 5%. Compelling opportunity. Yield is 5.34%. (Analysts’ price target is $95.45)
Gordon Reid
Price
$88.330
Owned
Yes
DON'T BUY
DON'T BUY
August 2, 2019
Has gone down a lot due to arthritis drug coming off patent. Earnings have been disappointing which pushed down the price further. Unsure if they can rebuild revenues to the same levels as before. Competition is now coming from generics and biosimilars, and would prefer medical device companies.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 2, 2019
Has gone down a lot due to arthritis drug coming off patent. Earnings have been disappointing which pushed down the price further. Unsure if they can rebuild revenues to the same levels as before. Competition is now coming from generics and biosimilars, and would prefer medical device companies.
David Driscoll
Price
$65.310
Owned
No
DON'T BUY
DON'T BUY
July 25, 2019
Avoid this one. Made a plan to do a very large acquisition, because their core line is declining. Allocating capital, and taking on debt, to mask a problem, and that's a red flag. Value trap.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 25, 2019
Avoid this one. Made a plan to do a very large acquisition, because their core line is declining. Allocating capital, and taking on debt, to mask a problem, and that's a red flag. Value trap.
COMMENT
COMMENT
July 18, 2019

Issue is that longer run pipeline is coming to an end. The quest is always for the next big drug out there. Trying to buy Allergan, whose big thing is botox. Political pressure on lower drug prices. Monster yield of over 6.5%.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 18, 2019

Issue is that longer run pipeline is coming to an end. The quest is always for the next big drug out there. Trying to buy Allergan, whose big thing is botox. Political pressure on lower drug prices. Monster yield of over 6.5%.

Bryden Teich
Price
$68.250
Owned
Unknown
COMMENT
COMMENT
July 18, 2019

Good news, bad news. Dividend is beautiful, Q1 beat, cheap valuation, raised outlook for 2019. Problem is it's really levered to Humira, so a one-trick pony. Trying to buy Allergan to diversify. Likes it at a lower level, but cautious. Not really for an RRSP. (Analysts’ price target is $83.70)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 18, 2019

Good news, bad news. Dividend is beautiful, Q1 beat, cheap valuation, raised outlook for 2019. Problem is it's really levered to Humira, so a one-trick pony. Trying to buy Allergan to diversify. Likes it at a lower level, but cautious. Not really for an RRSP. (Analysts’ price target is $83.70)

Greg Newman
Price
$68.250
Owned
Unknown
HOLD
HOLD
July 17, 2019
Abbvie has Humira, an $18-20 billion arthritis drug that will lose patent protection. ABBV bought Allergan under pressure to diversify--they needed to. They at 7.5x earnings with little growth after 2021. The Allergan purchase won't add much growth, but will lessen risk; Abbvie won't need to rely so much on Humira for revenues. The Allergan deal isn't done yet, but he likes it. Likes ABBV's dividend.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 17, 2019
Abbvie has Humira, an $18-20 billion arthritis drug that will lose patent protection. ABBV bought Allergan under pressure to diversify--they needed to. They at 7.5x earnings with little growth after 2021. The Allergan purchase won't add much growth, but will lessen risk; Abbvie won't need to rely so much on Humira for revenues. The Allergan deal isn't done yet, but he likes it. Likes ABBV's dividend.
Paul MacDonald
Price
$68.320
Owned
Yes
BUY
BUY
July 9, 2019
It's come off a lot, so there's opportunity. He doesn't know the stock well, but the chart suggests a buy right now.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 9, 2019
It's come off a lot, so there's opportunity. He doesn't know the stock well, but the chart suggests a buy right now.
Elliott Fishman
Price
$71.240
Owned
Unknown
BUY
BUY
May 3, 2019

Good entry point. Main drug Humira is $20B per year, and yes, its patent will expire in 2021. But they've been reinvesting that cash cow in other drugs. Paying 9x earnings, so it's cheap. Could consolidate around $100. Great dividend, balance sheet. Own it in a basket.

Show full opinionHide full opinion

Good entry point. Main drug Humira is $20B per year, and yes, its patent will expire in 2021. But they've been reinvesting that cash cow in other drugs. Paying 9x earnings, so it's cheap. Could consolidate around $100. Great dividend, balance sheet. Own it in a basket.

Paul MacDonald
Price
$78.710
Owned
Unknown
DON'T BUY
DON'T BUY
April 22, 2019
A fine company. Its major product is Humira, the biggest drug in the world in terms of sales and it amounts to 65% of ABBV's revenue. ABBV's dividend is sound, but ABBV will have to go through a transition, like merge with another comapny and develop other drugs, to take the pressure off Humira.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 22, 2019
A fine company. Its major product is Humira, the biggest drug in the world in terms of sales and it amounts to 65% of ABBV's revenue. ABBV's dividend is sound, but ABBV will have to go through a transition, like merge with another comapny and develop other drugs, to take the pressure off Humira.
Gordon Reid
Price
$78.150
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
April 4, 2019
(A Top Pick Apr 12/18, Down 7%) The only big pharma name that has a single digit P/E. Nice dividend yield over 5%. It is under pressure now because their arthritis drug is facing competition from generics and it is 60% of their revenues. The dividend yield acts as a support now. He is holding and monitoring M&A activity.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 4, 2019
(A Top Pick Apr 12/18, Down 7%) The only big pharma name that has a single digit P/E. Nice dividend yield over 5%. It is under pressure now because their arthritis drug is facing competition from generics and it is 60% of their revenues. The dividend yield acts as a support now. He is holding and monitoring M&A activity.
Stan Wong
Price
$82.810
Owned
Yes
HOLD
HOLD
March 21, 2019
They have Humera which makes up 62% of their revenue. This is not up-coming in the business but it represents some patent risk as it comes off patent in 4 years in the US. There will be competition around the world before then but not significant. They have to back stop this with other offerings. It could be through a purchase of a pipeline or something else. As time goes on you are going to get less and less benefit from this drug as an investment.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
March 21, 2019
They have Humera which makes up 62% of their revenue. This is not up-coming in the business but it represents some patent risk as it comes off patent in 4 years in the US. There will be competition around the world before then but not significant. They have to back stop this with other offerings. It could be through a purchase of a pipeline or something else. As time goes on you are going to get less and less benefit from this drug as an investment.
Gordon Reid
Price
$81.240
Owned
Unknown
HOLD
HOLD
February 28, 2019
It has been a tough pharma name. It is the only single digit P/E on the large pharma space. There is execution risk. Probably the dividend yield is safe. He would put a stop loss at the beneath the $78 level.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 28, 2019
It has been a tough pharma name. It is the only single digit P/E on the large pharma space. There is execution risk. Probably the dividend yield is safe. He would put a stop loss at the beneath the $78 level.
Stan Wong
Price
$79.240
Owned
Yes
DON'T BUY
DON'T BUY
February 21, 2019
The valuation is low and dividend is high. It cold be a trap. They focus in Humara. There is pressure from competition. He wouldn't be buying here as it carries more risk than it looks like.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 21, 2019
The valuation is low and dividend is high. It cold be a trap. They focus in Humara. There is pressure from competition. He wouldn't be buying here as it carries more risk than it looks like.
Greg Newman
Price
$78.750
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
February 4, 2019
(A Top Pick Mar 23/18, Down 16%) He thinks this is a really good sector. The seasonality doesn't come in for a while yet. There is a double bottom, which is positive. There are few sectors that look like they are in a secular bull market like this one.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 4, 2019
(A Top Pick Mar 23/18, Down 16%) He thinks this is a really good sector. The seasonality doesn't come in for a while yet. There is a double bottom, which is positive. There are few sectors that look like they are in a secular bull market like this one.
BUY
BUY
November 7, 2018
Just reported earnings last week, beating the street by 6%. It's been sideways, but pays a 4.9% dividend that should grow. Trades at 10x forward earnings at a 11% growth rate. But the market isn't recognizing this now. It's a good healthcare name, and healthcare has been outperforming the S&P in the current late cycle. ABBV has beaten earnings many quarters in a row.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 7, 2018
Just reported earnings last week, beating the street by 6%. It's been sideways, but pays a 4.9% dividend that should grow. Trades at 10x forward earnings at a 11% growth rate. But the market isn't recognizing this now. It's a good healthcare name, and healthcare has been outperforming the S&P in the current late cycle. ABBV has beaten earnings many quarters in a row.
Stan Wong
Price
$86.960
Owned
Yes
HOLD
HOLD
September 12, 2018

Likes it, even though flat this year. Pays a nice dividend of 4.1%, which is expected to grow. Likes the healthcare space. Hold on to it and collect the dividend.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
September 12, 2018

Likes it, even though flat this year. Pays a nice dividend of 4.1%, which is expected to grow. Likes the healthcare space. Hold on to it and collect the dividend.

Stan Wong
Price
$93.240
Owned
Yes
WATCH
WATCH
August 21, 2018

This is a fine company. Its primary product is Humira, the most successful drug in the history of the pharmaceutical industry. It represents about 60% of AbbVie’s earnings, which means that AbbVie’s portfolio is not well diversified. This is not unusual for pharma companies. The drug will not go off patent for a few years, but the clock is ticking. The question to ask is whether the company has good replacements in the works.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 21, 2018

This is a fine company. Its primary product is Humira, the most successful drug in the history of the pharmaceutical industry. It represents about 60% of AbbVie’s earnings, which means that AbbVie’s portfolio is not well diversified. This is not unusual for pharma companies. The drug will not go off patent for a few years, but the clock is ticking. The question to ask is whether the company has good replacements in the works.

Gordon Reid
Price
$97.740
Owned
Unknown
BUY
BUY
July 5, 2018

Is the yield sustainable? They are one of the largest biotech companies out there. They have one primary drug called Humera. It is an $18 billion dollar drug. They made a number of acquisitions. He sees the dividend as sustainable. Good valuation.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 5, 2018

Is the yield sustainable? They are one of the largest biotech companies out there. They have one primary drug called Humera. It is an $18 billion dollar drug. They made a number of acquisitions. He sees the dividend as sustainable. Good valuation.

Paul MacDonald
Price
$94.480
Owned
Yes
BUY
BUY
June 22, 2018

Nice little pharmaceutical name. 23% EPS growth. Trading at a reasonable 12 multiple. At these levels is OK to accumulate.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
June 22, 2018

Nice little pharmaceutical name. 23% EPS growth. Trading at a reasonable 12 multiple. At these levels is OK to accumulate.

Greg Newman
Price
$95.550
Owned
No
DON'T BUY
DON'T BUY
April 24, 2018

A bad acquisition two years ago hit them badly after that new company suffered a negative drug trial. Then, the stock dropped and he sold. There's probably still value in this stock, but he'd rather buy something else.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 24, 2018

A bad acquisition two years ago hit them badly after that new company suffered a negative drug trial. Then, the stock dropped and he sold. There's probably still value in this stock, but he'd rather buy something else.

James Telfser
Price
$91.360
Owned
No
TOP PICK
TOP PICK
April 12, 2018

A spin-off from Abbott Laboratories (ABT-N). Strong exposure to immunology and oncology medicines. Dividend Yield of 4.2%. The stock sold off because they had a setback on a cancer drugs, but it is overdone in his opinion. Great way to own a strong growing pharma company. (Analysts’ price target is $120.27)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 12, 2018

A spin-off from Abbott Laboratories (ABT-N). Strong exposure to immunology and oncology medicines. Dividend Yield of 4.2%. The stock sold off because they had a setback on a cancer drugs, but it is overdone in his opinion. Great way to own a strong growing pharma company. (Analysts’ price target is $120.27)

Stan Wong
Price
$92.120
Owned
Yes
TOP PICK
TOP PICK
March 23, 2018

He holds this in a pure technical system portfolio. It was down 13% yesterday and they decided to step in. A lung cancer drug recently announced disappointing results. They see health care in a secular bull market. A hot pick today.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
March 23, 2018

He holds this in a pure technical system portfolio. It was down 13% yesterday and they decided to step in. A lung cancer drug recently announced disappointing results. They see health care in a secular bull market. A hot pick today.

STRONG BUY
STRONG BUY
March 21, 2018

Really likes this. They put up a monster quarter earlier this year as well as surprise drug trials for dermatitis that came in strong. They've won some patents. It's a $20-billion cash cow that they're reinvesting, some in partnerships with companies like J&J. Everything is working for it.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
March 21, 2018

Really likes this. They put up a monster quarter earlier this year as well as surprise drug trials for dermatitis that came in strong. They've won some patents. It's a $20-billion cash cow that they're reinvesting, some in partnerships with companies like J&J. Everything is working for it.

Paul MacDonald
Price
$112.450
Owned
Yes
COMMENT
COMMENT
September 19, 2017

(Market Call Minute.) A company that was spun off from Abbott Labs (ABT-N) 2 or 3 years ago. A great company, but 66% of their revenue comes from 1 drug, Humira, the best selling drug in the world.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
September 19, 2017

(Market Call Minute.) A company that was spun off from Abbott Labs (ABT-N) 2 or 3 years ago. A great company, but 66% of their revenue comes from 1 drug, Humira, the best selling drug in the world.

Gordon Reid
Price
$86.370
Owned
Unknown
BUY
BUY
September 14, 2017

You absolutely have to hold on to it if you have a 2 year outlook. Humera is the largest selling drug in the world. They are forever in patent disputes. They have taken this cash cow and used the proceeds to reinvest in their pipeline. They have a great balance sheet and a great yield. We are seeing great results from their trials. It should have double digit growth and should be at 15 times. It should consolidate higher than where it is.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
September 14, 2017

You absolutely have to hold on to it if you have a 2 year outlook. Humera is the largest selling drug in the world. They are forever in patent disputes. They have taken this cash cow and used the proceeds to reinvest in their pipeline. They have a great balance sheet and a great yield. We are seeing great results from their trials. It should have double digit growth and should be at 15 times. It should consolidate higher than where it is.

Paul MacDonald
Price
$89.220
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
August 24, 2017

(Top Pick Jun 23/16, Up 23.30%) He still likes it and it is one of his favourite healthcare names. It has a 12 times PE and 8% long time growth rate. It trades at a discount to its peer group. Humeria is 60% of their revenues so we have to watch this concentration risk.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 24, 2017

(Top Pick Jun 23/16, Up 23.30%) He still likes it and it is one of his favourite healthcare names. It has a 12 times PE and 8% long time growth rate. It trades at a discount to its peer group. Humeria is 60% of their revenues so we have to watch this concentration risk.

Stan Wong
Price
$72.110
Owned
Unknown
DON'T BUY
DON'T BUY
June 21, 2017

(Market Call Minute.) The spinoff from Abbott Labs (ABT-N). What makes him hesitate about this is that it is more of a 1 product company with their Humira drug. It represents about 65% of their total revenue, so that presents risks.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
June 21, 2017

(Market Call Minute.) The spinoff from Abbott Labs (ABT-N). What makes him hesitate about this is that it is more of a 1 product company with their Humira drug. It represents about 65% of their total revenue, so that presents risks.

Gordon Reid
Price
$71.340
Owned
Unknown
COMMENT
COMMENT
May 10, 2017

This is kind of the by-product of one of these ultra blockbuster drugs. Their anti-inflammatory franchise is the largest selling drug right now. The company has done a good job of building out their pipeline. They have a cancer drug that is expected to be one of the top 10 by 2020. May 17 is a key date for the company as there is a challenge. Trading at 12X earnings, and going down to 10X with the dividend yield under 4%, so he would be cautious until May 17.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
May 10, 2017

This is kind of the by-product of one of these ultra blockbuster drugs. Their anti-inflammatory franchise is the largest selling drug right now. The company has done a good job of building out their pipeline. They have a cancer drug that is expected to be one of the top 10 by 2020. May 17 is a key date for the company as there is a challenge. Trading at 12X earnings, and going down to 10X with the dividend yield under 4%, so he would be cautious until May 17.

Paul MacDonald
Price
$65.980
Owned
Yes
PAST TOP PICK
PAST TOP PICK
April 20, 2017

(A Top Pick Dec 23/16. Up 4%.) A one trick pony with their drug Humira. Valuation is quite reasonable and is going to be 12-13X projected earnings. A lot of that is based on sales of Humira, a life altering drug, which accounts for over 60% of their revenues. Made 2 very large acquisitions in the past few years, and we are starting to see some of those drugs in the pipeline getting approved.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 20, 2017

(A Top Pick Dec 23/16. Up 4%.) A one trick pony with their drug Humira. Valuation is quite reasonable and is going to be 12-13X projected earnings. A lot of that is based on sales of Humira, a life altering drug, which accounts for over 60% of their revenues. Made 2 very large acquisitions in the past few years, and we are starting to see some of those drugs in the pipeline getting approved.

Lorne Zeiler
Price
$63.780
Owned
Yes
HOLD
HOLD
February 22, 2017

He is on the more optimistic side of this company. It has Humira, the largest selling drug in inflammatory related diseases. Because of that, they are going off patent. Everybody knows there is going to be competition for Humira, which he feels is being factored in to their forward earnings. They’ve known this too and have been building out their pipelines. He likes their 4% dividend. PE is going from 11 to 9 next year, a one-time PEG ratio. You are not paying a lot for the growth.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 22, 2017

He is on the more optimistic side of this company. It has Humira, the largest selling drug in inflammatory related diseases. Because of that, they are going off patent. Everybody knows there is going to be competition for Humira, which he feels is being factored in to their forward earnings. They’ve known this too and have been building out their pipelines. He likes their 4% dividend. PE is going from 11 to 9 next year, a one-time PEG ratio. You are not paying a lot for the growth.

Paul MacDonald
Price
$61.360
Owned
Yes
TOP PICK
TOP PICK
December 23, 2016

Thinks healthcare has been an un-forgotten asset class. As a result, there are a lot of companies with compelling valuations. This is trading at about 13.5X earnings. The majority of that comes from the auto immune therapy product, Humira, that really changes people’s lives. This will contribute about $17 billion to total earnings next year. They are seeing huge growth for emerging markets. It has come off patent, but this is an infusion medication with numerous patents around it. They’ve got a good pipeline, because they have made a number of acquisitions. They are expecting earnings growth of about 30% over the next 4 years. Dividend yield of 4.11%. (Analysts’ price target is $71.94.)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
December 23, 2016

Thinks healthcare has been an un-forgotten asset class. As a result, there are a lot of companies with compelling valuations. This is trading at about 13.5X earnings. The majority of that comes from the auto immune therapy product, Humira, that really changes people’s lives. This will contribute about $17 billion to total earnings next year. They are seeing huge growth for emerging markets. It has come off patent, but this is an infusion medication with numerous patents around it. They’ve got a good pipeline, because they have made a number of acquisitions. They are expecting earnings growth of about 30% over the next 4 years. Dividend yield of 4.11%. (Analysts’ price target is $71.94.)

Lorne Zeiler
Price
$62.340
Owned
Yes
COMMENT
COMMENT
July 29, 2016

Its main product is Humira which works on the immune system. Basically for rheumatoid arthritis, IBD, any of the diseases that act on the immune system. Accounts for close to 60% of their revenue. They just had a great quarter. Saw 17% increase in sales for Humira. Has a fantastic pipeline and very aggressive growth targets. Trades at a pretty reasonable valuation considering it is a growth company. They anticipate double digit growth in each of the next 4 years, and to get revenues up to $37 billion a year. If successful and are able to get their operating margins where they say, by 2020, based on current valuations of 14.5X earnings, you will be paying about 8X.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 29, 2016

Its main product is Humira which works on the immune system. Basically for rheumatoid arthritis, IBD, any of the diseases that act on the immune system. Accounts for close to 60% of their revenue. They just had a great quarter. Saw 17% increase in sales for Humira. Has a fantastic pipeline and very aggressive growth targets. Trades at a pretty reasonable valuation considering it is a growth company. They anticipate double digit growth in each of the next 4 years, and to get revenues up to $37 billion a year. If successful and are able to get their operating margins where they say, by 2020, based on current valuations of 14.5X earnings, you will be paying about 8X.

Lorne Zeiler
Price
$66.230
Owned
Yes
TOP PICK
TOP PICK
June 23, 2016

From a valuation perspective, he likes this a lot. This was a spinoff from Abbott Labs (ABT-N) in 2013. They are more of a research based pharmaceutical global name. Has a really good pipeline with 20 new products and indications coming through in the next few years through 2020. Shares are pretty attractively valued, trading at a forward price earnings multiple of only 12X. Long-term EPS growth rate is only 13%. You also get a 3.7% dividend yield, which is expected to grow at almost double digit over the next few years.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
June 23, 2016

From a valuation perspective, he likes this a lot. This was a spinoff from Abbott Labs (ABT-N) in 2013. They are more of a research based pharmaceutical global name. Has a really good pipeline with 20 new products and indications coming through in the next few years through 2020. Shares are pretty attractively valued, trading at a forward price earnings multiple of only 12X. Long-term EPS growth rate is only 13%. You also get a 3.7% dividend yield, which is expected to grow at almost double digit over the next few years.

Stan Wong
Price
$61.310
Owned
Yes
SELL
SELL
June 15, 2016

This is a result of a spinoff from Abbott Labs 2 or 3 years ago, and they took the pharmaceutical portion, which consisted primarily of 1 drug, Humira. That drug makes up 60%-65% of their revenue, which gives him great pause. Companies, where a large percentage of their revenues are based on one product is a worry. Believes the Humira patent comes off in a couple of years.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
June 15, 2016

This is a result of a spinoff from Abbott Labs 2 or 3 years ago, and they took the pharmaceutical portion, which consisted primarily of 1 drug, Humira. That drug makes up 60%-65% of their revenue, which gives him great pause. Companies, where a large percentage of their revenues are based on one product is a worry. Believes the Humira patent comes off in a couple of years.

Gordon Reid
Price
$60.400
Owned
No
PAST TOP PICK
PAST TOP PICK
November 3, 2015

(A Top Pick Oct 2/14. Up 14.9%.) They use the specialty Pharma’s that Valeant (VRX-T) is in trouble with, but it is not a huge portion of their revenues. It is widely speculated that they will use their cash to make an acquisition as opposed to buying back stock. If so, that should improve the stock price. If it doesn’t, then he thinks it will be a good take out candidate for somebody else.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 3, 2015

(A Top Pick Oct 2/14. Up 14.9%.) They use the specialty Pharma’s that Valeant (VRX-T) is in trouble with, but it is not a huge portion of their revenues. It is widely speculated that they will use their cash to make an acquisition as opposed to buying back stock. If so, that should improve the stock price. If it doesn’t, then he thinks it will be a good take out candidate for somebody else.

Andy Nasr
Price
$53.260
Owned
Yes
COMMENT
COMMENT
May 8, 2015

If you want to find a way to get yourself mangled, get into Biotech’s. They are expensive and a lot of them are trading on the hopes that whatever they are doing will get approved. Approval rate of these things is so low that it makes it a bit of a gamble. This one is a cut above the pure, speculative biotechs because they have stuff and they actually earn money. Trading about 15% above its FMV. However, earnings forecasts have been kind of flat lining recently. Has pretty good support technically around $60.

Show full opinionHide full opinion

If you want to find a way to get yourself mangled, get into Biotech’s. They are expensive and a lot of them are trading on the hopes that whatever they are doing will get approved. Approval rate of these things is so low that it makes it a bit of a gamble. This one is a cut above the pure, speculative biotechs because they have stuff and they actually earn money. Trading about 15% above its FMV. However, earnings forecasts have been kind of flat lining recently. Has pretty good support technically around $60.

Ross Healy
Price
$65.240
Owned
Unknown
DON'T BUY
DON'T BUY
March 12, 2015

Abbot (ABT-N) spun them off. She kept the labs division. She decided not to keep ABBV-N because of the dependence on Humira.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
March 12, 2015

Abbot (ABT-N) spun them off. She kept the labs division. She decided not to keep ABBV-N because of the dependence on Humira.

PAST TOP PICK
PAST TOP PICK
November 28, 2014

(A Top Pick Nov 14/13. Up to 48.85%.) Sold his holdings. Healthcare is identifiable, as clearly in a secular bull market for investors. He prefers focusing on the whole sector.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 28, 2014

(A Top Pick Nov 14/13. Up to 48.85%.) Sold his holdings. Healthcare is identifiable, as clearly in a secular bull market for investors. He prefers focusing on the whole sector.

PAST TOP PICK
PAST TOP PICK
October 31, 2014

(A Top Pick Nov 14/13. Up 37.05%.) Exited his position. One of the big drivers for him to get out was the split as he likes to hold whole positions. A little overbought right now and they could come back to around $52. This whole space is really good. If you own, continue to Hold. (See Top Picks.)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
October 31, 2014

(A Top Pick Nov 14/13. Up 37.05%.) Exited his position. One of the big drivers for him to get out was the split as he likes to hold whole positions. A little overbought right now and they could come back to around $52. This whole space is really good. If you own, continue to Hold. (See Top Picks.)

TOP PICK
TOP PICK
October 2, 2014

The acquisition should be accretive. They were a one drug portfolio before this. Their HEP-C drug competes well with Gilead’s.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
October 2, 2014

The acquisition should be accretive. They were a one drug portfolio before this. Their HEP-C drug competes well with Gilead’s.

Andy Nasr
Price
$56.670
Owned
Yes
PAST TOP PICK
PAST TOP PICK
August 27, 2014

(A Top Pick Sept 18/13. Up 20.17%.) Sold his holdings, but is now looking for an opportunity to get back in. Believes biotech and healthcare will be meaningful to society or move markets to change the world the way computers did.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 27, 2014

(A Top Pick Sept 18/13. Up 20.17%.) Sold his holdings, but is now looking for an opportunity to get back in. Believes biotech and healthcare will be meaningful to society or move markets to change the world the way computers did.

SELL
SELL
August 20, 2014

(Market Call Minute.) This is a spin off from Abbott Labs (ABT-N). What concerns him is that they own Humera, a great drug, but it is coming off patent in 2016 and represents about 65% of their business.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 20, 2014

(Market Call Minute.) This is a spin off from Abbott Labs (ABT-N). What concerns him is that they own Humera, a great drug, but it is coming off patent in 2016 and represents about 65% of their business.

Gordon Reid
Price
$55.060
Owned
No
PAST TOP PICK
PAST TOP PICK
April 7, 2014

(A Top Pick March 1/13. Up 38.65%.) Has been pretty volatile in the last little while. If it breaks down, it could go down to $48. Healthcare is still in a secular bull market, which is really positive. This is the place to be for the next 20 years.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 7, 2014

(A Top Pick March 1/13. Up 38.65%.) Has been pretty volatile in the last little while. If it breaks down, it could go down to $48. Healthcare is still in a secular bull market, which is really positive. This is the place to be for the next 20 years.

TOP PICK
TOP PICK
November 14, 2013

Has a fantastic mix of assets. Earnings have been fantastic. Long-term chart looks fantastic. Another big driver is that the whole healthcare space has come out of the woods. The next 10 years looks really good for the space.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 14, 2013

Has a fantastic mix of assets. Earnings have been fantastic. Long-term chart looks fantastic. Another big driver is that the whole healthcare space has come out of the woods. The next 10 years looks really good for the space.

TOP PICK
TOP PICK
September 18, 2013

Undervalued, experimental medicines is the cure for an ailing portfolio. Well-run company. Healthcare is in a secular bull market. He would wait for a pullback or a breakout. Yield of 3.38%.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
September 18, 2013

Undervalued, experimental medicines is the cure for an ailing portfolio. Well-run company. Healthcare is in a secular bull market. He would wait for a pullback or a breakout. Yield of 3.38%.

TOP PICK
TOP PICK
April 8, 2013

Healthcare is in a secular trend. This sector has the mother of all bases. Spun out of Abbot labs. He would add to this at $38/9. This is the second inning of healthcare across the board. You are getting a bit of a discount because of the spin out.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 8, 2013

Healthcare is in a secular trend. This sector has the mother of all bases. Spun out of Abbot labs. He would add to this at $38/9. This is the second inning of healthcare across the board. You are getting a bit of a discount because of the spin out.

TOP PICK
TOP PICK
March 1, 2013

Has a really good pipeline. Has a slight upward trend with a little bit of a channel. Feels the Humera drug will continue driving sales. Nice yield of 4.23%. Pharmaceuticals are in a really new bull market.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
March 1, 2013

Has a really good pipeline. Has a slight upward trend with a little bit of a channel. Feels the Humera drug will continue driving sales. Nice yield of 4.23%. Pharmaceuticals are in a really new bull market.

COMMENT
COMMENT
February 26, 2013

Abbott Labs (ABT-N) Split into 2 companies. This one has the pharmaceuticals. One drug accounts for 50% of their revenues and the patent comes off in 2016. Big, big risk. They are drastically looking to replace this drug. Generating huge margins. Huge amount of free cash flow. (See Top Picks.)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 26, 2013

Abbott Labs (ABT-N) Split into 2 companies. This one has the pharmaceuticals. One drug accounts for 50% of their revenues and the patent comes off in 2016. Big, big risk. They are drastically looking to replace this drug. Generating huge margins. Huge amount of free cash flow. (See Top Picks.)

Barry Schwartz
Price
$37.090
Owned
Yes
TOP PICK
TOP PICK
February 15, 2013

This was a spinoff from Abbott Labs (ABT-N). People are selling this because they don’t know what it is. His model price is $50, an upside of 37%. Yield of 4.3%.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 15, 2013

This was a spinoff from Abbott Labs (ABT-N). People are selling this because they don’t know what it is. His model price is $50, an upside of 37%. Yield of 4.3%.

Brian Acker, CA
Price
$37.580
Owned
Yes
DON'T BUY
DON'T BUY
January 10, 2013

Wouldn’t look at this one too closely because it is very concentrated. Their Humira drug makes up a large percentage of their total revenues and goes off patent in 2016.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
January 10, 2013

Wouldn’t look at this one too closely because it is very concentrated. Their Humira drug makes up a large percentage of their total revenues and goes off patent in 2016.

Gordon Reid
Price
$34.000
Owned
No
Showing 1 to 79 of 79 entries
  • «
  • 1
  • »

AbbVie Inc.(ABBV-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 12

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 13

Stockchase rating for AbbVie Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

AbbVie Inc.(ABBV-N) Frequently Asked Questions

What is AbbVie Inc. stock symbol?

AbbVie Inc. is a American stock, trading under the symbol ABBV-N on the New York Stock Exchange (ABBV). It is usually referred to as NYSE:ABBV or ABBV-N

Is AbbVie Inc. a buy or a sell?

In the last year, 13 stock analysts published opinions about ABBV-N. 12 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for AbbVie Inc..

Is AbbVie Inc. a good investment or a top pick?

AbbVie Inc. was recommended as a Top Pick by The Monthly Gems by Allan Tong on 2020-10-05. Read the latest stock experts ratings for AbbVie Inc..

Why is AbbVie Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is AbbVie Inc. worth watching?

13 stock analysts on Stockchase covered AbbVie Inc. In the last year. It is a trending stock that is worth watching.

What is AbbVie Inc. stock price?

On 2021-08-04, AbbVie Inc. (ABBV-N) stock closed at a price of $115.08.